NCT00555204 - Safety and Efficacy Study of ABT-089 in Adults With Mild to Moderate Alzheimer's Disease | Biotech Hunter

Enrollment

337

Participants

Timeline

Start Date

November 30, 2007

Primary Completion Date

June 30, 2009

Conditions

Alzheimer's Disease

Interventions

DRUG

ABT-089

10 mg - capsules once daily for 12 weeks

DRUG

ABT-089

5 mg - capsules once daily for 12 weeks

DRUG

ABT-089

15 mg - capsules once daily for 12 weeks

DRUG

ABT-089

20 mg - capsules once daily for 12 weeks

DRUG

ABT-089

30 mg - capsules once daily for 12 weeks

DRUG

ABT-089

35 mg - capsules once daily for 12 weeks

DRUG

placebo

placebo - capsules once daily for 12 weeks

Trial Locations (42)

10021

New York

10312

Staten Island

10454

The Bronx

12208

Albany

19046

Jenkintown

19401

Norristown

27104

Winston-Salem

28601

Hickory

33009

Hallendale

33016

Hialeah

33180

Miami

33351

Sunrise

33407

West Palm Beach

33409

West Palm Beach

33418

Palm Beach Gardens

33445

Delray Beach

33613

Tampa

33770

Largo

33901

Fort Myers

34613

Brooksville

42003

Paducah

44106

Cleveland

45459

Centerville

46260

Indianapolis

49503

Grand Rapids

63141

St Louis

76309

Wichita Falls

78229

San Antonio

85006

Phoenix

85351

Sun City

90404

Santa Monica

92108

San Diego

92705

Santa Ana

93720

Fresno

06518

Hamden

06510

New Haven

01201

Pittsfield

07740

Long Branch

07110

Nutley

08540

Princeton

07450

Ridgewood

05201

Bennington